[
  {
    "title": "1 Healthcare Stock on Our Watchlist and 2 to Brush Off",
    "published": 1742562068,
    "posting_price": 60.43999863,
    "close_price": 61.91999817,
    "percent_change": 2.44870876
  },
  {
    "title": "Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More",
    "published": 1742489100,
    "posting_price": 60.25999832,
    "close_price": 60.58000183,
    "percent_change": 0.53103803
  },
  {
    "title": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
    "published": 1742461785,
    "posting_price": 60.25999832,
    "close_price": 60.58000183,
    "percent_change": 0.53103803
  },
  {
    "title": "Stoke CEO exits; Medicare drug price talks advance",
    "published": 1742299500,
    "posting_price": 61.02999878,
    "close_price": 60.0,
    "percent_change": -1.68769261
  },
  {
    "title": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
    "published": 1742243527,
    "posting_price": 60.0,
    "close_price": 62.00999832,
    "percent_change": 3.3499972
  },
  {
    "title": "Top Midday Decliners",
    "published": 1742234374,
    "posting_price": 60.0,
    "close_price": 62.00999832,
    "percent_change": 3.3499972
  },
  {
    "title": "Incyte stock hit by 11% despite paediatric dermatology trials hitting target",
    "published": 1742231465,
    "posting_price": 60.0,
    "close_price": 62.00999832,
    "percent_change": 3.3499972
  },
  {
    "title": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
    "published": 1742227236,
    "posting_price": 60.0,
    "close_price": 62.00999832,
    "percent_change": 3.3499972
  },
  {
    "title": "Incyte Is Today\u2019s Worst S&P 500 Stock. Here\u2019s Why.",
    "published": 1742224860,
    "posting_price": 60.0,
    "close_price": 62.00999832,
    "percent_change": 3.3499972
  },
  {
    "title": "The past three years for Incyte (NASDAQ:INCY) investors has not been profitable",
    "published": 1713186886,
    "posting_price": 53.90999985,
    "close_price": 53.43000031,
    "percent_change": -0.89037199
  },
  {
    "title": "Certain\u00a0Biotech Investors Get an Early Look at Results. Is That Fair?",
    "published": 1713173400,
    "posting_price": 53.90999985,
    "close_price": 53.43000031,
    "percent_change": -0.89037199
  },
  {
    "title": "Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings",
    "published": 1712926811,
    "posting_price": 54.72000122,
    "close_price": 53.84999847,
    "percent_change": -1.58991727
  },
  {
    "title": "Incyte Corp. stock outperforms competitors despite losses on the day",
    "published": 1712895660,
    "posting_price": 54.72000122,
    "close_price": 53.84999847,
    "percent_change": -1.58991727
  },
  {
    "title": "Incyte to Report First Quarter Financial Results",
    "published": 1712836800,
    "posting_price": 55.34000015,
    "close_price": 54.91999817,
    "percent_change": -0.75894828
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)",
    "published": 1712569260,
    "posting_price": 54.97000122,
    "close_price": 55.04999924,
    "percent_change": 0.14553032
  },
  {
    "title": "Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion",
    "published": 1712471400
  },
  {
    "title": "Biotech Executive Who Bet on Rival\u2019s Stock Committed Insider Trading, Jury Says",
    "published": 1712408160
  },
  {
    "title": "Jury sides with SEC in trial over insider trading charges against former pharma executive",
    "published": 1712401200
  },
  {
    "title": "Top buy-rated stocks and sell-rated stocks within Health Care - Citi",
    "published": 1712225880,
    "posting_price": 55.54999924,
    "close_price": 54.99000168,
    "percent_change": -1.00809643
  },
  {
    "title": "Incyte Corp. stock underperforms Wednesday when compared to competitors",
    "published": 1712118120,
    "posting_price": 55.84000015,
    "close_price": 55.31000137,
    "percent_change": -0.94913821
  },
  {
    "title": "Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia",
    "published": 1711974600,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  },
  {
    "title": "Top 20 S&P 500 stocks by hedge fund net exposure - BofA",
    "published": 1711966320,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  },
  {
    "title": "Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024",
    "published": 1711966036,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  },
  {
    "title": "Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA",
    "published": 1711960800,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  },
  {
    "title": "Incyte gets payment from CMS Skinhealth for povorcitinib commercialization",
    "published": 1711957380,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  },
  {
    "title": "Incyte, CMS enter collaboration, license agreement for povorcitinib in China",
    "published": 1711957080,
    "posting_price": 56.97000122,
    "close_price": 56.63999939,
    "percent_change": -0.57925544
  }
]